Combinations for the treatment of parkinsonism containing selective NMDA antagonists
AssigneePfizer Inc.
InventorsBertrand L. Chenard, Frank S. Menniti
Life of this patent
Estimating the term…
Abstract
This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.
Claims5
A method of treating Parkinson's Disease in a mammal comprising administering to said mammal a Parkinson's Disease treating synergistic effective amounts of a combination of (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol and levodopa.
A pharmaceutical composition comprising a Parkinson's Disease treating synergistic effective amounts of a combination of (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol and levodopa;
- and a pharmaceutically acceptable diluent or carrier.
A method for achieving a synergistic antiparkinson effect in a mammal in need thereof which comprises administering to said mammal synergistic effective amounts of two therapeutic agents:
- (a) a forebrain selective NMDA antagonist, wherein said NMDA antagonist is (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol;
- and
- (b) an excitatory feedback enhancing agent, wherein said excitatory feedback enhancing agent is levodopa,
- wherein the amount of (a) alone and the amount of (b) alone is insufficient to achieve the therapeutic effect;
- and
- wherein the combined effect of the amounts of the therapeutic agents administered is greater than the sum of the therapeutic effects of the amounts of the individual therapeutic agents separately administered.
Dependencies are inferred from the claim text.